CTIS2023-508735-31-00进行中（未招募）1 期
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002 - AV-101-003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 462
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Consented to participate in the LTE and has successfully completed the placebo-controlled 24-week Study AV-101-002., Female subjects of childbearing potential who have agreed to continue to use a highly effective form of contraception during the LTE and for at least 30 days after completing or discontinuing study treatment.
排除标准
- •The Investigator believes that it would not be in the best interest of the subject to be included in the LTE e.g., for clinical or social reasons., Subjects who were not compliant with study medication in AV-101-002 as assessed by the Investigator.
研究者
相似试验
进行中（未招募）
1 期
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)Pulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077729Term: Pulmonary arterial hypertension WHO functional class IIISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077730Term: Pulmonary arterial hypertension WHO functional class IVSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077740Term: Pulmonary arterial hypertension WHO functional class IISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-006864-25-IEAerovate Therapeutics, Inc.462
进行中（未招募）
1 期
Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)EUCTR2021-006864-25-DEAerovate Therapeutics, Inc.462
进行中（未招募）
1 期
Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)Pulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077729Term: Pulmonary arterial hypertension WHO functional class IIISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077730Term: Pulmonary arterial hypertension WHO functional class IVSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077740Term: Pulmonary arterial hypertension WHO functional class IISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-006864-25-GRAerovate Therapeutics, Inc.462
尚未招募
3 期
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002Pulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH)NL-OMON53603Aerovate Therapeutics, Inc9
进行中（未招募）
1 期
Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)Pulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077729Term: Pulmonary arterial hypertension WHO functional class IIISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077730Term: Pulmonary arterial hypertension WHO functional class IVSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077740Term: Pulmonary arterial hypertension WHO functional class IISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-006864-25-NLAerovate Therapeutics, Inc.462